On November 5, 2022, Beroni Group was invited to participate in the “Third TMU Pharmaceutical Forum and Annual Meeting of Pharmaceutical Branch of China National Health Association”, which was sponsored by the College of Pharmacy of Tianjin Medical University and the Pharmaceutical Branch of the China National Health Association under the guidance of Tianjin Medical University and China National Health Association. The event was also jointly sponsored by the Health Statistics and Information Branch of the Tianjin Preventive Medicine Association, Tianjin Study Group of Pharmaceutical Branch of China National Health Association and Tianjin Biomedical Discipline Innovation Consortium.
The forum invited a number of medical experts, clinical medical experts, medical education and pharmacy management experts who are mainly from Shenyang Pharmaceutical University, Nankai University, Tianjin Medical University, Tianjin First Central Hospital, Tianjin Third Central Hospital, Tianjin Fifth Central Hospital, Peking Union Medical College Hospital, Tianjin Medical University Chu Hsien-I Memorial Hospital, Tianjin Medical University General Hospital, Tianjin Medical University Cancer Institute and Hospital, the First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, the Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, the Blood Diseases Hospital of the Chinese Academy of Medical Sciences, Tianjin Children Hospital, Tianjin Huanhu Hospital,Tianjin TEDA Hospital. Mr. Jacky Zhang, Executive Chairman of Beroni Group, Dr. Eric Wang, Technical Director, and Miss. Jiaxing Zhu, Business Development Department attended the forum. Dr. Eric Wang made an academic report.
At the beginning of the forum, Mr. Weizhen Gao, Chairman of the meeting, the representative of China National Health Association, and Professor of Tianjin Medical University, leaders of Tianjin Medical University and Academician Changxiao Liu of Chinese Academy of Engineering delivered a speech respectively. The forum consists of a main forum, a satellite conference and three sub forums. The experts made reports on drug action mechanism, medical research ideas and tools, clinical medication management, medical and health reform, etc.
Dr. Eric Wang made an academic report on Beroni’s “Innovative Drug for Advanced Solid Tumor – PENAO” project. PENAO is a new and unique “First in-Class” anti-tumor compound, which contains active arsenic molecules and can take effect through the blood brain barrier and is effective for all solid tumors. As a key research project of Beroni in cancer treatment, PENAO has completed Phase I clinical trial in Australia and started Phase II clinical trial. It is expected to complete the registration of IND in China in 2023 and start the clinical trial in China.
PENAO has been shown to be effective in preclinical trials for a variety of cancers, including ovarian cancer, breast cancer and pancreatic cancer. PENAO can also cross the blood-brain barrier and is expected to be a drug for the treatment of central nervous system brain cancer. Once successfully developed, PENAO will become the first-class ANT inhibitor for cancer treatment.
The forum responds to the national new medical reform policy and the healthy China strategy, conforms to the social development trend, and promotes the high quality development in medicine of Tianjin. Experts put forward many kinds of ideas on medical education, talent training, new drug research and development, clinical medicine and medical services and discuss key issues at the forum. As one of Tianjin pharmaceutical enterprises, Tianjin Beroni Biotechnology Co., Ltd. is also willing to contribute to Tianjin’s development in medicine and talent team building.
